Wellington Management Group LLP Has $948,000 Stock Position in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Wellington Management Group LLP cut its holdings in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 4.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,378 shares of the biotechnology company’s stock after selling 1,904 shares during the period. Wellington Management Group LLP owned about 0.26% of Anika Therapeutics worth $948,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. HighTower Advisors LLC grew its holdings in shares of Anika Therapeutics by 11.3% during the 3rd quarter. HighTower Advisors LLC now owns 15,883 shares of the biotechnology company’s stock valued at $387,000 after purchasing an additional 1,615 shares during the last quarter. Stonepine Capital Management LLC grew its position in Anika Therapeutics by 14.5% during the 3rd quarter. Stonepine Capital Management LLC now owns 189,308 shares of the biotechnology company’s stock worth $4,676,000 after acquiring an additional 23,911 shares during the last quarter. FMR LLC increased its holdings in Anika Therapeutics by 25.3% in the 3rd quarter. FMR LLC now owns 24,721 shares of the biotechnology company’s stock worth $611,000 after purchasing an additional 4,996 shares in the last quarter. Segall Bryant & Hamill LLC raised its position in Anika Therapeutics by 1.7% in the third quarter. Segall Bryant & Hamill LLC now owns 108,799 shares of the biotechnology company’s stock valued at $2,687,000 after purchasing an additional 1,794 shares during the last quarter. Finally, Quest Partners LLC boosted its stake in shares of Anika Therapeutics by 115.8% during the third quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock valued at $171,000 after purchasing an additional 3,705 shares in the last quarter. Institutional investors and hedge funds own 91.53% of the company’s stock.

Analysts Set New Price Targets

ANIK has been the subject of several recent research reports. StockNews.com downgraded Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Barrington Research decreased their price target on shares of Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a research report on Friday, November 1st.

Anika Therapeutics Stock Performance

NASDAQ:ANIK opened at $16.33 on Friday. The company has a market capitalization of $239.17 million, a PE ratio of -2.46 and a beta of 0.89. Anika Therapeutics, Inc. has a fifty-two week low of $15.82 and a fifty-two week high of $29.11. The company has a 50 day simple moving average of $19.32 and a two-hundred day simple moving average of $23.58.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.